Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

PURPOSE: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Devarakonda, Siddhartha, Rotolo, Federico, Tsao, Ming-Sound, Lanc, Irena, Brambilla, Elisabeth, Masood, Ashiq, Olaussen, Ken A., Fulton, Robert, Sakashita, Shingo, McLeer-Florin, Anne, Ding, Keyue, Le Teuff, Gwénaël, Shepherd, Frances A., Pignon, Jean-Pierre, Graziano, Stephen L., Kratzke, Robert, Soria, Jean-Charles, Seymour, Lesley, Govindan, Ramaswamy, Michiels, Stefan
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2018
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804865/
https://ncbi.nlm.nih.gov/pubmed/30106638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.78.1963
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια